Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associate...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

Ontherag Aug. 4 at 3:58 PM

$PDSB Annual shareholder meeting next Monday 8am!

0 · Reply

Jayy25 Aug. 4 at 2:25 PM

$PDSB its so weird…. i cant believe its getting notifications about getting delisted…its like they havent posted any news for 12 weeks

0 · Reply

Ontherag Aug. 3 at 7:14 PM

$PDSB Nothing like a delist notice to get that share price moving!

0 · Reply

Test2025 Aug. 2 at 4:10 PM

$PDSB On July 30, 2026, PDS Biotechnology Corp received a warning from Nasdaq for its stock price falling below $1.00 over 30 consecutive days, with a compliance period until January 26, 2027, to rectify this issue.

0 · Reply

JFais Aug. 2 at 1:34 PM

$SLS (No Position) Haven't gotten this much flak for posting devil's advocate since $PDSB Position sizing for longs should be "hope for the best, plan for the worst" That way, you'll live to fight another day (no matter the outcome) Wish each of you the best & LT success 🙂

10 · Reply

rwol9999 Jul. 31 at 8:43 PM

$PDSB OH nice delist notice! FFS🤐

0 · Reply

Ontherag Jul. 31 at 5:58 PM

$PDSB Maybe some fireworks next week, until then have a great weekend!

1 · Reply

Kosmokrat Jul. 30 at 12:11 PM

$PDSB I really hope the support at $0.50 holds. Now I am pretty sure we'll see the 50's again this summer, as I don't expect any news from $PDSB before September, other than the Q2 numbers, which will be a non-event. And knowing that they never announce anything new at the quarterly conference calls and answer any questions regarding their clinical trials very cautious, like "Everything is progressing well according to plan, we have no updates to announce at this point in time."

1 · Reply

Mr_Charlie Jul. 30 at 10:13 AM

$PDSB bought another 2000 shares yesterday at 0.66. I will be buying more if it keeps going down.

1 · Reply

Ontherag Jul. 29 at 7:54 PM

$PDSB Annual shareholder meeting coming soon, yay!

0 · Reply

PDS Biotechnology registers to sell 13.32M shares of common stock for holders

Jul 10, 2026, 8:00 AM EDT - 25 days ago

PDS Biotechnology Registration statement: Registration filing

Jun 26, 2026, 8:00 AM EDT - 5 weeks ago

PDS Biotechnology Proxy statement: Proxy filing

Jun 26, 2026, 8:00 AM EDT - 5 weeks ago

PDS Biotechnology Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 7 weeks ago

PDS Biotechnology Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 2 months ago

PDS Biotechnology Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

PDS Biotechnology Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

PDS Biotechnology Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

May 6, 2026, 8:00 AM EDT - 3 months ago

PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results

Apr 24, 2026, 8:00 AM EDT - 3 months ago

PDS Biotechnology Registration statement: Registration filing

Apr 22, 2026, 7:00 AM EDT - 3 months ago

PDS Biotechnology Slides: Corporate presentation

2026-04-15T13:37:04.000Z - 3 months ago

PDS Biotechnology announces positive Phase 2 trial data for PDS01ADC

Apr 15, 2026, 8:45 AM EDT - 3 months ago

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

Mar 30, 2026, 8:00 AM EDT - 4 months ago

PDS Biotechnology Earnings Call Transcript: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 4 months ago

PDS Biotechnology Annual report: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 4 months ago

PDS Biotechnology Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 4 months ago

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

Mar 24, 2026, 4:05 PM EDT - 4 months ago

PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

Feb 20, 2026, 8:30 AM EST - 5 months ago

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

Jan 28, 2026, 8:45 AM EST - 6 months ago

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Jan 22, 2026, 8:45 AM EST - 6 months ago

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

Jan 9, 2026, 8:45 AM EST - 7 months ago

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Dec 9, 2025, 8:00 AM EST - 8 months ago

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 2, 2025, 8:30 AM EST - 8 months ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 8:00 AM EST - 9 months ago

PDS Biotechnology Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

PDS Biotechnology Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

PDS Biotechnology Earnings release: Q3 2025

Nov 13, 2025, 7:30 AM EST - 9 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 9 months ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 9 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 9 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 9 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 11 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Registration statement: Registration Filing

Aug 25, 2025, 8:30 AM EDT - 1 year ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 17, 2025, 12:00 PM EDT - 1 year ago

PDS Biotechnology Transcript: Status Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Registration statement: Registration Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Transcript: Study Update

May 23, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Press release: Study Update

May 22, 2025, 5:26 PM EDT - 1 year ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

May 21, 2025, 5:20 PM EDT - 1 year ago

PDS Biotechnology Transcript: A.G.P. Virtual Annual Healthcare Company Showcase

May 20, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 1 year ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 23, 2025, 10:16 AM EDT - 1 year ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 2:30 PM EDT - 1 year ago

PDS Biotechnology Transcript: Life Sciences Virtual Investor Conference

Mar 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 1 year ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Quarterly report: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Earnings release: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 9, 2024, 8:00 AM EDT - 2 years ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 2 years ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 9:30 AM EDT - 2 years ago

PDS Biotechnology Quarterly report: Q2 2024

Aug 13, 2024, 9:30 AM EDT - 2 years ago

PDS Biotechnology Earnings release: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Ontherag Aug. 4 at 3:58 PM

$PDSB Annual shareholder meeting next Monday 8am!

0 · Reply

Jayy25 Aug. 4 at 2:25 PM

$PDSB its so weird…. i cant believe its getting notifications about getting delisted…its like they havent posted any news for 12 weeks

0 · Reply

Ontherag Aug. 3 at 7:14 PM

$PDSB Nothing like a delist notice to get that share price moving!

0 · Reply

Test2025 Aug. 2 at 4:10 PM

0 · Reply

JFais Aug. 2 at 1:34 PM

10 · Reply

rwol9999 Jul. 31 at 8:43 PM

$PDSB OH nice delist notice! FFS🤐

0 · Reply

Ontherag Jul. 31 at 5:58 PM

$PDSB Maybe some fireworks next week, until then have a great weekend!

1 · Reply

Kosmokrat Jul. 30 at 12:11 PM

1 · Reply

Mr_Charlie Jul. 30 at 10:13 AM

$PDSB bought another 2000 shares yesterday at 0.66. I will be buying more if it keeps going down.

1 · Reply

Ontherag Jul. 29 at 7:54 PM

$PDSB Annual shareholder meeting coming soon, yay!

0 · Reply

EddieH2020 Jul. 29 at 4:05 PM

$PDSB Pigs get fed, you know the rest. @Ontherag

0 · Reply

Mr_Charlie Jul. 29 at 3:35 PM

$PDSB I buy 0.66.

1 · Reply

Juliodough Jul. 28 at 8:25 PM

$PDSB what was that last trade about at 4:07…weird. Anyway, I hope and pray the best for all of you guys

1 · Reply

Ontherag Jul. 28 at 5:31 PM

$PDSB 34k volume, complete nonsense

2 · Reply

Jayy25 Jul. 28 at 4:52 PM

$PDSB approaching 3 months no communication at all…… this is either the cockiest company of all time or the dumbest company of all time.

0 · Reply

Ontherag Jul. 28 at 4:14 PM

$PDSB

1 · Reply

Mr_Charlie Jul. 28 at 11:43 AM

$PDSB it is very hard to know which one is worst, the science or the management.

0 · Reply

dig_THAT_girl Jul. 28 at 12:44 AM

$PDSB honest question, where is all the bullishness coming from over the last few days? Did I miss some news or something? Last I checked this stock has been steadily eating dick for the last couple of months.

2 · Reply

LabPsycho Jul. 27 at 4:12 PM

$PDSB The direction this thing was headed was revealed to me long ago with ceo double speak.

0 · Reply

JohntyCT Jul. 27 at 3:56 PM

$PDSB tick tock Frank. You set yourself up: (1) the FDA said you could amend your protocol, when are you announcing the restart of P3? (2) you got YA to give you a lifeline and you gave YA the ATM to pay it off, but it’s not happening at 65 cents per share….what’s your catalyst? It’s do or die time, Frank. Tick tock.

0 · Reply

Llamalamb2921 Jul. 27 at 3:33 PM

$PDSB Subcutaneous Keytruda injection over about a minute is being actively advertised on TV. Such a natural fit with Versamune. I wish we were privy to any past or present conversations with Merck.

0 · Reply

wyoming2020 Jul. 26 at 3:08 PM

$PDSB communication is horrible. The board at least needs to give update and come out of hiding

0 · Reply

Market Cap	38.37M
Revenue (ttm)	0.00
Net Income (ttm)	-34.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	2.73

Volume	191,236
Avg Vol	584,458
Day's Range	N/A - N/A
Shares Out	55.92M
Stochastic %K	51%
Beta	1.59
Analysts	Strong Sell
Price Target	$7.50